The EUROclass trial: defining subgroups in common variable immunodeficiency

Area of Science:

• Immunology
• Clinical Medicine
• Flow Cytometry

Background:

• Common Variable Immunodeficiency (CVID) exhibits significant heterogeneity, necessitating refined classification systems.
• Existing classification schemes for CVID require consensus to better address pathogenic mechanisms and clinical relevance.
• Flowcytometric B-cell phenotyping and clinical course are key parameters for CVID subtyping.

Purpose of the Study:

• To develop a consensus classification for CVID by integrating existing schemes.
• To correlate B-cell subpopulations with clinical manifestations in CVID patients.
• To propose an improved classification system (EUROclass) for CVID based on B-cell phenotypes and clinical data.

Main Methods:

• European multicenter trial involving 303 CVID patients.
• Clinical evaluation and flowcytometric B-cell phenotyping.
• Analysis of B-cell subpopulations including switched memory B cells, CD21(low) B cells, and transitional B cells.

Main Results:

• Significant association found between granulomatous disease, autoimmune cytopenia, and splenomegaly in CVID patients.
• Severe reduction in switched memory B cells observed in most patients, linked to increased risk of splenomegaly and granulomatous disease.
• Expansion of CD21(low) B cells correlated with splenomegaly, while transitional B-cell expansion was linked to lymphadenopathy.

Conclusions:

• The proposed EUROclass system categorizes CVID patients into distinct groups based on B-cell levels (absent, reduced switched memory, expanded transitional, or CD21(low) B cells).
• This classification aids in identifying patients with severe B-cell differentiation defects and those with potential germinal center development issues.
• Further research is needed to elucidate the underlying defects associated with expanded transitional and CD21(low) B cells in CVID.